申请人:The Boots Company PLC
公开号:EP0135367A1
公开(公告)日:1985-03-27
Novel quinolones of formula I
and pharmaceutically acceptable acid addition salts thereof in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond, R is hydrogen, 1-methyl or 2-lower alkyl; R, is lower alkyl; R2 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, cyano, difluoromethoxy, methylsulphinyl, phenylsulphinyl or the group -NR4R5 or the N-oxide thereof wherein R4 and R5, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical; and R3 is hydrogen, fluoro, lower alkyl or lower alkoxy provided that, when R3 is lower alkoxy, R2 is other than lower alkoxy have utility as antihypertensive agents. Processes for preparing the quinolones and pharmaceutical compositions containing them are disclosed.
式 I 的新型喹诺酮类药物
及其药学上可接受的酸加成盐,其中喹诺酮环的位置2和3之间的虚线代表任选键,R是氢、1-甲基或2-低级烷基;R,是低级烷基;R2是氢、卤素、低级烷基、低级烷氧基、三氟甲基、氰基、二氟甲氧基、甲基亚磺酰基、苯基亚磺酰基或基团 -NR4R5 或其 N-氧化物,其中 R4 和 R5(可以相同或不同)是低级烷基,或与所连接的氮原子一起形成吡咯烷基、哌啶基或吗啉基;R3是氢、氟、低级烷基或低级烷氧基,但当R3是低级烷氧基时,R2是低级烷氧基以外的基团。本研究还公开了制备喹诺酮类药物和含有它们的药物组合物的工艺。